Featured Stories
Volkswagen of America Reports Q2 2026 Sales
HERNDON, Virginia, July 11 -- Volkswagen Group of America issued the following news release on July 10, 2026:
* * *
Volkswagen of America Reports Q2 2026 Sales
* Volkswagen Q2 2026 sales increased 24.9% YoY compared to Q2 2025
* Tiguan sales grew 152.5% YoY in Q2 and ID. Buzz sales grew 121.5% YoY
* Volkswagen sold 162,961 vehicles in H1 2026, a 2.3% increase from H1 2025
Reston, VA -- Today, Volkswagen of America released sales figures for Q2 2026.
* * *
About Volkswagen of America
Volkswagen of America, Inc. is an operating unit of Volkswagen Group of America, which is an indirect subsidiary
... Show Full Article
HERNDON, Virginia, July 11 -- Volkswagen Group of America issued the following news release on July 10, 2026:
* * *
Volkswagen of America Reports Q2 2026 Sales
* Volkswagen Q2 2026 sales increased 24.9% YoY compared to Q2 2025
* Tiguan sales grew 152.5% YoY in Q2 and ID. Buzz sales grew 121.5% YoY
* Volkswagen sold 162,961 vehicles in H1 2026, a 2.3% increase from H1 2025
Reston, VA -- Today, Volkswagen of America released sales figures for Q2 2026.
* * *
About Volkswagen of America
Volkswagen of America, Inc. is an operating unit of Volkswagen Group of America, which is an indirect subsidiaryof Volkswagen AG. Headquartered in Reston, Virginia, Volkswagen of America sells the Atlas, Atlas Cross Sport, Golf GTI, Golf R, ID.4, Jetta, Jetta GLI, Taos, and Tiguan vehicles through more than 600 independent U.S. dealers. Volkswagen Group of America operates a state-of-the-art assembly facility in Chattanooga, Tennessee which assembles Volkswagen brand vehicles including the Atlas and Atlas Cross Sport. Visit Volkswagen online at www.vw.com or media.vw.com to learn more.
* * *
Original text here: https://media.vw.com/releases/1930
[Category: BizTransportation]
Ropes & Gray Advised B Capital in Investor Group Acquisition of Russell Investments
BOSTON, Massachusetts, July 11 -- Ropes and Gray, a law firm, issued the following news:
* * *
Ropes & Gray Advised B Capital in Investor Group Acquisition of Russell Investments
Ropes & Gray represented B Capital along with the California Public Employees' Retirement System (CalPERS) in an investor consortium led acquisition of Russell Investments from existing owners TA Associates and Reverence Capital Partners. The transaction was announced on July 9 and is expected to close in the first quarter of 2027. Financial terms were not disclosed.
Russell Investments manages more than $416 billion
... Show Full Article
BOSTON, Massachusetts, July 11 -- Ropes and Gray, a law firm, issued the following news:
* * *
Ropes & Gray Advised B Capital in Investor Group Acquisition of Russell Investments
Ropes & Gray represented B Capital along with the California Public Employees' Retirement System (CalPERS) in an investor consortium led acquisition of Russell Investments from existing owners TA Associates and Reverence Capital Partners. The transaction was announced on July 9 and is expected to close in the first quarter of 2027. Financial terms were not disclosed.
Russell Investments manages more than $416 billionin assets under management and has achieved more than 15 percent organic growth over the past two years.
Russell Investments plans to use the backing of the new owners to broaden its open-architecture investment platform through enhanced technology, increased customization, advanced analytics, and expanded access to investment solutions.
B Capital is a multi-stage global investment firm with more than $12 billion in assets under management across multiple funds. The firm focuses on seed to late-stage venture growth investments primarily in the technology, healthcare and energy sectors.
The Ropes & Gray team included mergers & acquisitions partners Ariel Deckelbaum, Elizabeth Langton and Carl Marcellino, asset management partners Arthur Andersen, Eve Ellis, Alyssa Horton, Brynn Rail and Katie Waite, finance partner Dan Coyne, employment, executive compensation & benefits partners Jen Cormier, Matt Jones, and Josh Lichtenstein, litigation & enforcement partners Zak Goodwin, Ruchit Patel and Rob Skinner, IP transactions partner Jordan Altman, HSR partner Marta Kelly, tax partner Chris Roman, private equity counsel Jennifer Gorman, tax counsel Sara Clevering, litigation & enforcement counsel Kurt Fowler and Heather Sprague, and data, privacy & cybersecurity counsel Edward Machin.
* * *
URL: B Capital
* * *
Original text here: https://www.ropesgray.com/en/news-and-events/news/2026/07/ropes-gray-advised-b-capital-in-investor-group-acquisition-of-russell-investments
[Category: BizLaw/Legal]
Morgan Stanley Infrastructure Partners Enters Into Agreement to Acquire Majority Stake in Nicollin Environnement
NEW YORK, July 11 -- Morgan Stanley, a multinational financial services corporation, issued the following news release on July 10, 2026:
* * *
Morgan Stanley Infrastructure Partners Enters Into Agreement to Acquire Majority Stake in Nicollin Environnement
Morgan Stanley Investment Management (MSIM), through investment funds managed by Morgan Stanley Infrastructure Partners (MSIP), its private infrastructure investment platform, today announced it has entered into exclusivity and committed to complete the acquisition of a majority stake in Nicollin Environnement (Nicollin or the Company), a family-owned
... Show Full Article
NEW YORK, July 11 -- Morgan Stanley, a multinational financial services corporation, issued the following news release on July 10, 2026:
* * *
Morgan Stanley Infrastructure Partners Enters Into Agreement to Acquire Majority Stake in Nicollin Environnement
Morgan Stanley Investment Management (MSIM), through investment funds managed by Morgan Stanley Infrastructure Partners (MSIP), its private infrastructure investment platform, today announced it has entered into exclusivity and committed to complete the acquisition of a majority stake in Nicollin Environnement (Nicollin or the Company), a family-ownedFrench environmental platform focused on waste collection and sorting, urban street cleaning and water-related solutions. The Nicollin family will remain invested alongside MSIP and will continue to support the Company's next phase of growth.
Founded in 1945 and led by the Nicollin family for more than three generations, the Company is one of France's leading independent environmental platforms. Nicollin provides these essential environmental solutions to municipalities and businesses across France, operating through a national network of local centers. Nicollin manages approximately 360 public contracts and 8,000 private clients, supported by approximately 4,800 employees, a fleet of 2,900 vehicles, and a portfolio of strategically located, mission critical real property, including depots, transfer stations and sorting facilities.
"After more than 80 years of family ownership, we are proud to begin this next chapter with Morgan Stanley Infrastructure Partners, a partner that shares our vision for the future of Nicollin. Together, we will continue investing in growth, innovation and the environmental transition while preserving the values and culture that have shaped our company for three generations. By retaining an ownership stake, our family remains committed to supporting Nicollin and its teams for the long term," said Olivier Nicollin and Laurent Nicollin.
MSIP will support Nicollin's continued development, working alongside the Nicollin family and management team to advance operational excellence, renew and decarbonize the fleet, and strengthen its offerings to municipalities and corporate customers.
"We are thrilled at the prospect to partner with the Nicollin Family and management team through this strategic investment, which will support the next phase of the Company's growth," said Alfonso Gomez-Acebo, Managing Director at Morgan Stanley Infrastructure Partners. "Nicollin provides essential environmental solutions across France, supported by long-standing local relationships and a strong reputation for execution quality. We look forward to supporting the Company as it continues to invest in its people, fleet and infrastructure."
"Nicollin is a strong fit with MSIP's European infrastructure strategy, combining essential municipal solutions, resilient contractual revenues and clear opportunities to support the circular economy," said Alberto Donzelli, Co-Head of Europe for Morgan Stanley Infrastructure Partners.
The transaction is expected to close in the fourth quarter of 2026 upon completion of the mandatory information and consultation procedures with employee representative bodies and customary regulatory approvals.
Paul Hastings served as legal counsel to MSIP, with Natixis Partners serving as financial advisor. Clifford Chance served as legal counsel to the Nicollin family, with Rothschild & Co serving as financial advisor.
* * *
About Nicollin Environment
Founded in 1945, Nicollin Environnement is today the leading independent, family-owned French group in the environmental services sector.
For more than 80 years, the Group has grown around the values at the heart of its identity: people, close ties with the local communities it serves, and pride in a job well done.
Present across France, Nicollin Environnement supports municipalities and businesses in waste management, urban cleaning, and water and sanitation services.
With more than 4,800 employees, the Group is organized around two complementary divisions: the Environment division (waste management and urban cleaning) and the Water division (water management and sanitation).
For further information about Nicollin Environnement, please visit www.groupenicollin.com.
* * *
About Morgan Stanley Infrastructure Partners
Morgan Stanley Infrastructure Partners (MSIP) is a leading global private infrastructure investment platform with approximately $17 billion in capital commitments since inception. Founded in 2006, MSIP has invested in a diverse portfolio across transportation, digital, energy transition, and water and waste. MSIP targets assets that provide essential public goods and services with the potential for value creation through active ownership. For further information about Morgan Stanley Infrastructure Partners, please visit Morgan Stanley Infrastructure Partners.
* * *
About Morgan Stanley Investment Management
Morgan Stanley Investment Management, together with its investment advisory affiliates, has more than 1,300 investment professionals around the world and $1.9 trillion in assets under management or supervision as of March 31, 2026. Morgan Stanley Investment Management strives to provide outstanding long-term investment performance, service, and a comprehensive suite of investment management solutions to a diverse client base, which includes governments, institutions, corporations and individuals worldwide. For further information about Morgan Stanley Investment Management, please visit www.morganstanley.com/im.
* * *
About Morgan Stanley
Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 42 countries, the Firm's employees serve clients worldwide including corporations, governments, institutions and individuals. For further information about Morgan Stanley, please visit www.morganstanley.com.
* * *
Original text here: https://www.morganstanley.com/press-releases/msip-to-acquire-majority-stake-in-nicollin-environnement
[Category: BizFinancial Services]
Hughes Hubbard Files Suit Against New York State Over Inadequate Shelter Allowances Alongside Legal Aid Society, Empire Justice Center and Bond, Schoeneck & King
NEW YORK, July 11 -- Hughes Hubbard and Reed, a law firm, issued the following news:
* * *
Hughes Hubbard Files Suit Against New York State Over Inadequate Shelter Allowances Alongside Legal Aid Society, Empire Justice Center and Bond, Schoeneck & King
Firm challenges decades-old public assistance rates that fall far below housing costs.
Highlights
* Class action challenges New York's public assistance shelter allowance schedule.
* Plaintiffs argue outdated rates violate the state constitution.
* Allowances as low as $215 in NYC fall far short of HUD fair market rent.
-
Hughes Hubbard,
... Show Full Article
NEW YORK, July 11 -- Hughes Hubbard and Reed, a law firm, issued the following news:
* * *
Hughes Hubbard Files Suit Against New York State Over Inadequate Shelter Allowances Alongside Legal Aid Society, Empire Justice Center and Bond, Schoeneck & King
Firm challenges decades-old public assistance rates that fall far below housing costs.
Highlights
* Class action challenges New York's public assistance shelter allowance schedule.
* Plaintiffs argue outdated rates violate the state constitution.
* Allowances as low as $215 in NYC fall far short of HUD fair market rent.
-
Hughes Hubbard,alongside the Legal Aid Society, Empire Justice Center and Bond, Schoeneck & King, filed a class-action lawsuit against the New York State Office of Temporary and Disability Assistance (OTDA), challenging the state's public assistance shelter allowance schedule. The suit, filed on behalf of individuals and families in New York City and upstate New York, argues the allowances have remained largely unchanged for decades despite rising housing costs, contributing to homelessness across the state.
The plaintiffs allege that OTDA has failed to set shelter allowances at levels that enable recipients to secure housing, violating the state's constitutional obligation to provide aid, care and support to those in need.
According to the complaint, current allowances are far out of step with market rents. In New York City, a single adult receiving public assistance is allocated $215 per month for rent, and a family of three receives $400 - well below the U.S. Department of Housing and Urban Development's fair market rent levels of $2,406 and $2,780, respectively.
"Public assistance shelter allowances must reflect the reality facing New Yorkers struggling to keep a roof over their heads," said Fara Tabatabai. "Aligning shelter allowances with the actual cost of rent is essential to ensure that vulnerable individuals and families can avoid eviction and homelessness. Together with The Legal Aid Society, Bond, Schoeneck and King, and Empire Justice Center, we're proud to file this suit to protect New Yorkers' basic housing rights."
Fara Tabatabai leads the Hughes Hubbard team.
* * *
Original text here: https://www.hugheshubbard.com/news-insights/news/hughes-hubbard-files-suit-against-new-york-state-over-inadequate-shelter-allowances-alongside-legal-aid-society-empire-justice-center-and-bond-schoeneck-king
[Category: BizLaw/Legal]
GSK's Licensor Hansoh Pharma Announces Positive Phase III Results for Ris-Rez in China Patient Population
LONDON, England, July 11 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on July 10, 2026:
* * *
GSK's licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population
* ARTEMIS-008, a phase III study conducted for China, met its primary endpoint of overall survival in advanced or relapsed small-cell lung cancer
* First positive phase III overall survival data for a B7-H3-targeted ADC in any tumour type
* GSK is advancing risvutatug rezetecan outside China across multiple tumour types, including lung cancer,
... Show Full Article
LONDON, England, July 11 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on July 10, 2026:
* * *
GSK's licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population
* ARTEMIS-008, a phase III study conducted for China, met its primary endpoint of overall survival in advanced or relapsed small-cell lung cancer
* First positive phase III overall survival data for a B7-H3-targeted ADC in any tumour type
* GSK is advancing risvutatug rezetecan outside China across multiple tumour types, including lung cancer,prostate cancer and other solid tumours
-
GSK plc (LSE/NYSE: GSK) licensor Hansoh Pharmaceutical Group Co., Ltd. today announced that ARTEMIS-008, its pivotal phase III trial evaluating risvutatug rezetecan (Ris-Rez) in patients with advanced or relapsed small-cell lung cancer (SCLC), met its primary endpoint of overall survival (OS). In the trial, conducted in patients in China, Ris-Rez demonstrated statistically significant and clinically meaningful improvements in OS compared with the standard of care, topotecan. Consistent benefit was also observed across key secondary endpoints, including progression-free survival. These data will be used by Hansoh Pharma for regulatory submission in China.
These are the first positive phase III overall survival data reported for a B7-H3-targeted antibody-drug conjugate (ADC) in any tumour type. The safety profile is consistent with prior Ris-Rez findings, and no new safety signals were identified.
GSK holds exclusive global rights to develop Ris-Rez outside mainland China, Hong Kong, Macau and Taiwan. GSK's broad clinical development programme includes studies in lung cancer, prostate cancer and other solid tumours, including the global phase III EMBOLD SCLC-301 trial in relapsed extensive-stage small-cell lung cancer (ES-SCLC) with pivotal data expected next year.
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK said: "These results are an important milestone as the first positive phase III overall survival data for a B7-H3-targeted ADC in any tumour type. Together, with other data generated to date, they further support the potential of B7-H3 as a promising target across lung cancer and other solid tumours and reinforce our continued development of Ris-Rez to improve standard of care in areas of high unmet need."
Most patients with ES-SCLC relapse after initial therapy and have limited treatment options, poor prognosis and significant treatment burden./1 B7-H3 is highly expressed in SCLC tumours/2,3 and the positive results from ARTEMIS-008 add to the growing body of evidence supporting the encouraging clinical activity and manageable safety profile of Ris-Rez in patients with ES-SCLC.
* * *
About risvutatug rezetecan
Ris-Rez is a novel investigational B7-H3-targeted ADC composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload. GSK acquired exclusive worldwide rights (excluding China's mainland, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to progress clinical development and commercialisation of Ris-Rez.
Regulatory designations received for Ris-Rez to date include orphan drug designations from the US Food and Drug Administration (FDA) and Japan's Ministry of Health, Labour and Welfare in SCLC and the European Medicines Agency (EMA) in a category of cancer that includes SCLC, called pulmonary neuroendocrine carcinoma; Priority Medicines (PRIME) Designation from the EMA for relapsed or refractory ES-SCLC; and Breakthrough Therapy Designations for relapsed or refractory ES-SCLC and relapsed or refractory osteosarcoma from the US FDA./4,5,6,7,8,9,10
* * *
GSK in oncology
Our ambition in oncology is to help increase overall quality of life, maximise survival and change the course of disease, expanding from our current focus on blood and gynaecologic cancers into lung and gastrointestinal cancers, as well as other solid tumours. This includes accelerating priority programmes such as antibody-drug conjugates targeting B7-H3 and B7-H4, and velzatinib, a highly selective KIT tyrosine kinase inhibitor.
* * *
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
* * *
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025, and GSK's Q1 Results for 2026.
* * *
References
1. G. Mountzios, et al. Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N Engl J Med, 393 (2025), pp. 349-361. DOI: 10.1056/NEJMoa2502099.
2. A.A. Getu, A. Tigabu, M. Zhou, J. Lu, 0. Fodstad, M. Tan. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development. Mol. Cancer, 22 (2023), p. 43, 10.1186/s12943-023-01751-9.
3. M. Altan, V. Pelekanou, K.A. Schalper, M. Toki, P. Gaule, K. Syrigos, R.S. Herbst, D.L. Rimm. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. Clin. Cancer Res., 23 (2017), pp. 5202-5209, 10.1158/1078-0432.Ccr-16-3107.
4. GSK. GSK receives US FDA Breakthrough Therapy Designation for its B7-H3-targeted antibody-drug conjugate in relapsed or refractory extensive-stage small-cell lung cancer. Available at: https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-fda-breakthrough-therapy-designation/.
5. GSK. GSK's B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in Japan. Available at: https://www.gsk.com/en-gb/media/press-releases/gsk-s-b7-h3-targeted-antibody-drug-conjugate-risvutatug-rezetecan-granted-orphan-drug-designation-for-small-cell-lung-cancer-in-japan/.
6. GSK. GSK's B7-H3-targeted antibody-drug conjugate, GSK'227, receives EMA Priority Medicines (PRIME) Designation in relapsed extensive-stage small-cell lung cancer. Available at: https://www.gsk.com/en-gb/media/press-releases/b7-h3-targeted-antibody-drug-conjugate-receives-ema-priority-medicines-designation-in-relapsed-extensive-stage-small-cell-lung-cancer/.
7. GSK. GSK's B7-H3-targeted antibody-drug conjugate, GSK'227, receives Orphan Drug Designation in the EU. Available at: https://www.gsk.com/en-gb/media/press-releases/gsk-s-b7-h3-targeted-antibody-drug-conjugate-gsk-227-receives-orphan-drug-designation-in-the-eu/.
8. GSK. GSK's B7-H3-targeted antibody-drug conjugate, GSK'227, receives EMA Priority Medicines (PRIME) Designation in relapsed extensive-stage small-cell lung cancer. Available at: https://www.gsk.com/en-gb/media/press-releases/b7-h3-targeted-antibody-drug-conjugate-receives-ema-priority-medicines-designation-in-relapsed-extensive-stage-small-cell-lung-cancer/.
9. GSK. GSK receives US FDA Breakthrough Therapy Designation for its B7-H3-targeted antibody-drug conjugate in relapsed or refractory extensive-stage small-cell lung cancer. Available at: https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-fda-breakthrough-therapy-designation/.
10. GSK. GSK's B7-H3-targeted antibody-drug conjugate, GSK'227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma. Available at: https://www.gsk.com/en-gb/media/press-releases/gsk-b7-h3-targeted-antibody-drug-conjugate-gsk227-receives-us-fda-breakthrough-therapy-designation-in-late-line-relapsed-or-refractory-osteosarcoma/.
* * *
Original text here: https://www.gsk.com/en-gb/media/press-releases/gsk-s-licensor-hansoh-pharma-announces-positive-phase-iii-results-for-ris-rez-in-china-patient-population/
[Category: BizPharmaceuticals]
Ford Appoints Matt VanKuiken Chief Government Affairs Officer
DEARBORN, Michigan, July 11 -- Ford Motor issued the following news on July 10, 2026:
* * *
Ford Appoints Matt VanKuiken Chief Government Affairs Officer
Ford Motor Company today announced that Matt VanKuiken has been named Chief Government Affairs Officer, effective Aug. 3.
VanKuiken joins Ford from BlackRock, where he served as director of Federal Government Affairs. Before joining BlackRock, VanKuiken spent 15 years in the U.S. Senate, including eight years as chief of staff to U.S. Sen. Debbie Stabenow.
At BlackRock, VanKuiken led strategies to advance policy priorities in Washington and
... Show Full Article
DEARBORN, Michigan, July 11 -- Ford Motor issued the following news on July 10, 2026:
* * *
Ford Appoints Matt VanKuiken Chief Government Affairs Officer
Ford Motor Company today announced that Matt VanKuiken has been named Chief Government Affairs Officer, effective Aug. 3.
VanKuiken joins Ford from BlackRock, where he served as director of Federal Government Affairs. Before joining BlackRock, VanKuiken spent 15 years in the U.S. Senate, including eight years as chief of staff to U.S. Sen. Debbie Stabenow.
At BlackRock, VanKuiken led strategies to advance policy priorities in Washington andstrengthened key relationships across the U.S. Senate, House of Representatives, and committee leadership.
This followed his time as chief of staff to Stabenow, where he managed daily operations across the senator's Washington, D.C., Michigan, committee and leadership offices.
In the Senate, VanKuiken helped advance legislation impacting the automotive industry, including USMCA negotiations, production tax credits under the Inflation Reduction Act, and evolving emissions standards.
"Matt's deep understanding of the auto industry and state, federal, and international policy makes him an invaluable asset to Ford," said Steven Croley, Ford's chief policy officer and general counsel. "As our industry navigates a time of rapid progress, Matt's leadership and experience will ensure Ford's voice is heard clearly around the world."
"I am thrilled to join Ford Motor Company at such a pivotal moment for the auto industry," said VanKuiken. "As a Michigan native, Ford's legacy of American manufacturing is personal, and I look forward to advocating for the company's priorities globally. I'm excited to work alongside this talented team as we manage the road ahead."
In his role, VanKuiken will lead Ford's global Government Affairs team, including engagement with state, federal, and international government officials.
He will oversee efforts to promote legislation, regulations, and policies that directly advance the Ford+ plan for growth and value creation.
* * *
Original text here: https://www.fromtheroad.ford.com/us/en/articles/2026/matt-vankuiken-ford-chief-government-affairs-officer
[Category: BizTransportation]
'Austin Monthly' Lists 53 Jackson Walker Attorneys Among "Austin's Top Attorneys" of 2026
AUSTIN, Texas, July 11 -- Jackson Walker, a law firm, issued the following news:
* * *
'Austin Monthly' Lists 53 Jackson Walker Attorneys Among "Austin's Top Attorneys" of 2026
Jackson Walker congratulates the 53 attorneys recognized among Austin Monthly's list of "Austin's Top Attorneys" for 2026. For recognition in the list, Austin attorneys must be nominated by their peers on the basis that they offer experienced counsel in one of 40 categories.
Congratulations to the following attorneys who were named to the list:
* Adam Aston - Appellate
* Peter Hansen - Appellate
* Danica Milios -
... Show Full Article
AUSTIN, Texas, July 11 -- Jackson Walker, a law firm, issued the following news:
* * *
'Austin Monthly' Lists 53 Jackson Walker Attorneys Among "Austin's Top Attorneys" of 2026
Jackson Walker congratulates the 53 attorneys recognized among Austin Monthly's list of "Austin's Top Attorneys" for 2026. For recognition in the list, Austin attorneys must be nominated by their peers on the basis that they offer experienced counsel in one of 40 categories.
Congratulations to the following attorneys who were named to the list:
* Adam Aston - Appellate
* Peter Hansen - Appellate
* Danica Milios -Appellate
* Jeffrey Oldham - Appellate
* Cody Vaughn - Appellate
* Tara Potts - Attorneys for Non-Profits
* Sarah Christian - Banking and Financial
* James Pledger - Banking and Financial
* Beau Butler - Bankruptcy and Workout
* Jennifer Wertz - Bankruptcy and Workout
* Marilyn Brown - Commercial Litigation
* Matt Dow - Commercial Litigation
* Sean Gallagher - Commercial Litigation
* Breck Harrison - Commercial Litigation
* Christopher Mugica - Commercial Litigation
* Joshua Romero - Commercial Litigation
* Scott Weatherford - Commercial Litigation
* Andrea Thai Egan - Corporate Counsel
* Brad Knippa - Corporate Finance Mergers and Acquisitions
* Michael Meskill - Corporate Finance Mergers and Acquisitions
* Jennifer Freel - Criminal Defense
* Brad Anderson - Eminent Domain
* Anne Derrig - Eminent Domain
* Noah Galton - Eminent Domain
* Lindsay Killeen - Eminent Domain
* Alicia French - Energy Oil and Gas
* Meghan Griffiths - Energy Oil and Gas
* Taylor Cummins - Government and Administrative
* Denise Rose - Government and Administrative
* Jack Skaggs - Health Care
* Raman Dewan - Intellectual Property Rights
* Temple Keller - Intellectual Property Rights
* Emilio Nicolas - Intellectual Property Rights
* Brian Prewitt - Intellectual Property Rights
* Paige Welch - Intellectual Property Rights
* Juan Alcala - International
* Alicia Duleba - Labor and Employment
* Alisha Mehta Adams - Land Use Environment
* Pamela Madere - Land Use Environment
* Aron Burnett - Real Estate
* Lenora DuBose - Real Estate
* Cassie Ross - Real Estate
* Michelle Smith - Real Estate
* Timothy Taylor - Real Estate
* Ali Andrews - Tax
* Steve Moore - Tax
* Sarah Pai - Tax
* Jessica Palvino - Tax
* Michael Baldwin - Wills Estates and Probate
* Tyson Ehlinger - Wills Estates and Probate
* Sam Hildebrand - Wills Estates and Probate
* Amanda Neinast - Wills Estates and Probate
* Erin Tuggle - Wills Estates and Probate
The full list of honorees can be found on Austin Monthly's "Austin's Top Attorneys 2026" (https://www.austinmonthly.com/top-attorneys/) directory.
* * *
About Jackson Walker
Since 1887, Jackson Walker has represented some of the most influential companies and business leaders in the world. Today, we remain firmly rooted in Texas while serving clients around the globe. With more than 500 attorneys, we are the largest law firm in the state. Jackson Walker consistently ranks among leading firms in Chambers and Partners, Best Law Firms(R) by Best Lawyers, and as a BTI Client Service A-Team based on feedback from corporate counsel.
* * *
Original text here: https://www.jw.com/news/austin-monthly-top-attorneys-2026/
[Category: BiLaw/Legal]
